Stock Analiz

DR Reddys Laboratories Ltd. (RDY) financials: revenue, earnings and cash flow

Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026

Summary

DR Reddys Laboratories’s revenue went from $2.1B in fiscal 2017 to $3.6B in fiscal 2026, growth of about 5.9% a year.

Net income in fiscal 2026 was $455M, a net margin of 12.8%; the best year in this period was 2024 with $668M.

Over the twelve months to September 30, 2026, revenue was $3.5B and net income $297M.

Free cash flow was $195M in fiscal 2026 and positive in 9 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2017: $2.1B172018: $2.2B182019: $2.2B192020: $2.3B202021: $2.6B212022: $2.8B222023: $3.0B232024: $3.4B242025: $3.8B252026: $3.6B26$3.6B
Net income
2018: $151M182019: $272M192020: $259M202021: $236M212022: $311M222023: $548M232024: $668M242025: $663M252026: $455M26$455M
Free cash flow
2018: $134M182019: $314M192020: $332M202021: $355M212022: $177M222023: $578M232024: $348M242025: $223M252026: $195M26$195M
EPS (diluted)
2018: $0.18182019: $0.33192020: $0.31202021: $0.28212022: $0.37222023: $0.66232024: $0.80242025: $0.79252026: $0.5526$0.55

Income statement

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$3.5B$3.6B$3.8B$3.4B$3.0B$2.8B$2.6B$2.3B$2.2B$2.2B$2.1B
Gross profit——$2.2B$2.0B$1.7B$1.5B$1.4B$1.2B$1.2B$1.2B—
Operating income——$842M$813M$695M$389M$332M$212M$302M$183M—
Net income$297M$455M$663M$668M$548M$311M$236M$259M$272M$151M—
EPS (diluted)$0.36$0.55$0.79$0.80$0.66$0.37$0.28$0.31$0.33$0.18—
R&D———————————
Revenue growth—−6.3%+13.8%+12.0%+5.9%+8.9%+12.0%+4.1%+2.0%+2.1%−7.2%

Cash flow

Fiscal yearTTM2026202520242023202220212020201920182017
Operating cash flow$328M$603M$545M$545M$716M$370M$488M$396M$415M$277M—
Capital spending-$278M-$408M-$322M-$197M-$138M-$193M-$133M-$64M-$101M-$143M—
Free cash flow$50M$195M$223M$348M$578M$177M$355M$332M$314M$134M—
Dividends paid$71M$71M$78M$80M$61M$55M$57M$52M$58M$61M$52M
Buybacks—————$0——$0$0—
Stock-based pay——$5M$5M$5M$8M$8M$7M$6M$7M—

Balance sheet

Fiscal yearTTM2026202520242023202220212020201920182017
Cash—$678M$678M$977M$752M$585M$473M$341M$358M$323M—
Debt—$537M$537M$225M$106M$433M$402M$235M$493M$776M$86M
Equity—$3.9B$3.9B$3.4B$2.8B$2.5B$2.4B$2.1B$2.0B$1.9B—
Total assets—$5.8B$5.8B$4.7B$3.9B$3.9B$3.6B$3.1B$3.3B$3.5B—
Shares (diluted)833M833M835M835M835M835M835M835M835M835M835M

Margins and returns

Fiscal yearTTM2026202520242023202220212020201920182017
Gross margin——58.5%58.6%56.6%53.1%54.3%53.8%54.2%53.7%—
Operating margin——22.1%24.3%23.2%13.8%12.8%9.2%13.6%8.4%—
Net margin8.5%12.8%17.4%19.9%18.3%11.0%9.1%11.2%12.2%6.9%—
FCF margin1.4%5.5%5.9%10.4%19.3%6.3%13.7%14.3%14.1%6.1%—
ROIC——14.1%17.5%17.8%9.7%7.8%7.3%10.0%4.6%—
ROE——17.0%19.9%19.5%12.4%10.0%12.6%13.4%7.8%—

Frequently asked questions

What is DR Reddys Laboratories’s annual revenue?

$3.6B in fiscal 2026 and $3.5B over the twelve months to September 30, 2026.

How much profit does DR Reddys Laboratories make?

Net income was $455M in fiscal 2026 (net margin 12.8%).

Is DR Reddys Laboratories’s revenue growing?

No: revenue fell 6.3% in fiscal 2026 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.